Brianna Goodman, | |
100 Spader Way, Broomfield, CO 80020 | |
(720) 887-2220 | |
(720) 887-2229 |
Full Name | Brianna Goodman |
---|---|
Gender | Female |
Speciality | Clinical Nurse Specialist - Community Health/public Health |
Location | 100 Spader Way, Broomfield, Colorado |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1861881211 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
364SC1501X | Clinical Nurse Specialist - Community Health/public Health | 0196160 (Colorado) | Primary |
Mailing Address | Practice Location Address |
---|---|
Brianna Goodman, 100 Spader Way, Broomfield, CO 80020 Ph: (720) 887-2220 | Brianna Goodman, 100 Spader Way, Broomfield, CO 80020 Ph: (720) 887-2220 |
News Archive
Scratching deep beneath the surface, a team of researchers from the University of California, San Diego School of Medicine and three South Korean institutions have identified two distinct neuronal signaling pathways activated by a topical cream used to treat a variety of skin diseases. One pathway produces the therapeutic benefit; the other induces severe itching as a side effect.
NASA awarded a research grant worth more than $9.8 million over five-years to the University of Texas Southwestern Medical Center in Dallas.
Australian researchers have discovered a viral link which they believe may help explain high blood pressure during pregnancy (pre-eclampsia) and pre-term birth.
A study by Hospital for Special Surgery researchers finds that body mass index (BMI) plays a role in rheumatoid arthritis (RA) patients' ability to achieve a sustained remission. Looking at patients who had received an RA diagnosis within the past 12 months, investigators found that those who were significantly underweight or overweight/obese were the least likely to remain in remission.
VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced the upcoming presentation of preclinical data from the company's lead program, VB-201, at the European League Against Rheumatism Annual European Congress of Rheumatology.
› Verified 6 days ago